A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease

Mansfield, J. C., Parkes, M., Hawthorne, A. B., Forbes, A., Probert, C. S. J., Perowne, R. C., Cooper, A., Zeldis, J. B., Manning, D. C. and Hawkey, C. J. (2007) A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Alimentary Pharmacology and Therapeutics, 26 (3). pp. 421-430. ISSN 0269-2813

Full text not available from this repository. (Request a copy)

Abstract

Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.

Item Type:	Article
Uncontrolled Keywords:	adolescent,adult,aged,crohn disease,double-blind method,female,humans,immunosuppressive agents,male,middle aged,placebos,severity of illness index,thalidomide,treatment outcome,venous thrombosis
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Depositing User:	Pure Connector
Date Deposited:	06 Aug 2014 10:50
Last Modified:	06 Feb 2025 05:07
URI:	https://ueaeprints.uea.ac.uk/id/eprint/49680
DOI:	10.1111/j.1365-2036.2007.03385.x

Actions (login required)

View Item